GSK’s Nucala (Mepolizumab) Secures the NMPA’s Approval for Treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Shots:
- The NMPA has approved Nucala as an add-on therapy with intranasal corticosteroids in CRSwNP adults with inadequately controlled disease. It is approved for patients (≥12yrs.) as an add-on treatment of severe eosinophilic asthma & for adults having eosinophilic granulomatosis with polyangiitis
- Approval was based on 2 P-III studies: MERIT assessing Nucala vs PBO in Japanese, Chinese & Russian subjects for 52wks. and SYNAPSE involving >400 subjects with this indication
- MERIT study, involving 163 patients, showed significantly improved nasal obstruction VAS score (mean difference: -1.43), QoL by SNOT-22 (difference: -10.63) & loss of smell VAS score (difference: -0.82) as well as reduced nasal polyp score at wk.52
Ref: GSK | Image: GSK
Related News:- GSK Reports the Data from the P-III (FIRST-ENGOT-OV44) Study Evaluating Zejula and Jemperli in 1L Advanced Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
